- Home
- CGEN vs GF Comparison
CGEN vs GF Comparison
Compare CGEN & GF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- GF
- Stock Information
- Founded
- CGEN 1993
- GF 1990
- Country
- CGEN Israel
- GF Germany
- Employees
- CGEN N/A
- GF N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- GF Investment Managers
- Sector
- CGEN Health Care
- GF Finance
- Exchange
- CGEN Nasdaq
- GF Nasdaq
- Market Cap
- CGEN 167.4M
- GF 155.4M
- IPO Year
- CGEN 2000
- GF N/A
- Fundamental
- Price
- CGEN $1.53
- GF $12.16
- Analyst Decision
- CGEN
- GF
- Analyst Count
- CGEN 0
- GF 0
- Target Price
- CGEN N/A
- GF N/A
- AVG Volume (30 Days)
- CGEN 236.0K
- GF 28.1K
- Earning Date
- CGEN 08-06-2025
- GF 01-01-0001
- Dividend Yield
- CGEN N/A
- GF 0.82%
- EPS Growth
- CGEN N/A
- GF N/A
- EPS
- CGEN N/A
- GF N/A
- Revenue
- CGEN $27,589,000.00
- GF N/A
- Revenue This Year
- CGEN N/A
- GF N/A
- Revenue Next Year
- CGEN $105.77
- GF N/A
- P/E Ratio
- CGEN N/A
- GF N/A
- Revenue Growth
- CGEN N/A
- GF N/A
- 52 Week Low
- CGEN $1.13
- GF $7.38
- 52 Week High
- CGEN $2.66
- GF $9.41
- Technical
- Relative Strength Index (RSI)
- CGEN 41.35
- GF 60.08
- Support Level
- CGEN $1.49
- GF $11.90
- Resistance Level
- CGEN $1.64
- GF $12.29
- Average True Range (ATR)
- CGEN 0.08
- GF 0.16
- MACD
- CGEN -0.02
- GF -0.02
- Stochastic Oscillator
- CGEN 25.00
- GF 47.30
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.